The combination of NUC-3373 plus pembrolizumab was generally well tolerated ... to have two Phase 2 product candidates in our portfolio, each with a distinct mechanism of action, that can potentiate ...

Dr. Zocca continued, “Our T-win platform generates off-the-shelf therapeutic cancer vaccine candidates with a unique mechanism of action, capable of both ... IO102-IO103 in combination with KEYTRUDA ® ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

"A highlight of the third quarter was the presentation of our validating COM701, COM902, pembrolizumab combination data in ... providing the opportunity to harness the unique mechanism of action of ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.